



FOR IMMEDIATE RELEASE

**LMA receives FDA approval to market urology device LMA StoneBreaker™
in the US**

Singapore, 17 May 2007 – Mainboard-listed LMA International NV (“LMA”), the global leader in the development and marketing of the LMA™ laryngeal mask airway range of supraglottic airway management devices, announced today that the Food and Drug Administration (“FDA”) has granted approval for LMA to commence marketing the LMA StoneBreaker™ device in the United States.

The revolutionary and innovative system, manufactured in Switzerland, received the CE mark in June 2006. The effectiveness of this kinetic intracorporeal lithotripsy technique has been proven by a peer-reviewed clinical trial and several hundred clinical cases to date. Sales of the device have already commenced in Europe and Asia.

LMA Group President and CEO Michael Ashton said, “We are extremely pleased with this latest development. Based on the positive response and increasing demand for the device in other parts of the world since its introduction last year, we anticipate demand from the US to fuel sales growth in the second half of FY2007.”

The LMA StoneBreaker™ is a portable intra-corporeal contact lithotripter, which effectively fragments stones in the urinary tract. This handheld system complements lithotripsy procedures performed with extra-corporeal shockwave lithotripsy devices by targeting kidney stones located in places which cannot be properly eliminated using this method.

- Ends -

For media queries, please contact:

Gavin Anderson & Company, Tel: +65 6339 9110

Sharon Seetho, Tel: +65 9009 8495, Email: sseetho@gavinanderson.com.sg

About LMA

Incorporated in the Netherlands Antilles in 1998, LMA listed on the Mainboard of the Singapore Exchange in March 2005. LMA designs, develops, markets and distributes medical equipment, principally the LMA™ laryngeal mask airway range of supraglottic airway management devices. These devices are used by physicians to allow respiration, provide ventilation to, and support the airway of patients undergoing surgical procedures and life-saving interventions. Since its first product, the LMA Classic™, was approved by the FDA for use in the United States in 1991, LMA's growth has been driven by the development of innovative products, geographic expansion, and increased customer awareness of the LMA™ laryngeal mask airway as an alternative airway management device. LMA has established a leading position in this growing market.

LMA has an office in Jersey, Channel Islands, and subsidiaries in Singapore, Bonn, Germany, San Diego, California and Melbourne, Australia. Through its 50 percent joint venture in LMA Urology Limited, the Group has a subsidiary in Gland, Switzerland to design, manufacture and distribute the LMA StoneBreaker™. DBS Bank and Credit Suisse were the Joint Global Coordinators and Joint Bookrunners for the Initial Public Offering of shares in LMA.